Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2021-01-11 Major Shareholding Noti…
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2021
Major Shareholding Notification Classification · 99% confidence The document is titled 'Voting Rights Announcements' and explicitly contains a 'Notification of Major Holdings' section detailing changes in voting rights percentages (e.g., from 0.03% to 3.10%) held by UBS Group AG/UBS AG in Biotest AG, referencing German Securities Trading Act (WpHG) articles. This structure perfectly matches the definition of a Major Shareholding Notification, which tracks changes in significant ownership thresholds.
2021-01-11 English
Biotest AG: Biotests Pentaglobin(R) is a treatment option for COVID-19 patients additionally affected by bacterial infections
Regulatory Filings Classification · 99% confidence The document is a press release disseminated via DGAP-News, dated November 26, 2020, announcing research updates regarding Biotest AG's product Pentaglobin(R) as a potential treatment option for COVID-19 patients with secondary bacterial infections. It contains key highlights, scientific rationale, and company background, but it is not a comprehensive financial report (like 10-K or IR), a transcript (CT), or a formal regulatory filing detailing insider trades (DIRS) or capital changes (CAP/SHA). It is an announcement of corporate/research news. Since it is a news announcement about a product/research update and not a formal financial report, the most appropriate category is 'Regulatory Filings' (RNS) as a general corporate announcement, or potentially 'Earnings Release' (ER) if it were tied to financial results, but here it is clearly a research/product update announcement. Given the options, RNS serves as the best general regulatory/news announcement fallback for non-financial/non-meeting specific corporate news.
2020-11-26 English
Biotest AG: Biotest increases adjusted 9-month EBIT by over 21% to 52 million
Earnings Release Classification · 100% confidence The document is a press release dated November 12, 2020, detailing financial results for the 'first nine months of the 2020 financial year' (Q1-Q3 results). It explicitly mentions 'Quarter Results' in the DGAP header and provides detailed figures for sales, adjusted EBIT, and EBIT for the nine-month period. This content aligns perfectly with the definition of a comprehensive financial report for a period shorter than a year. The document also mentions that the 'nine month report is available on the company’s website,' but the text provided *is* the summary of that report, making it an Interim/Quarterly Report (IR) rather than just a Report Publication Announcement (RPA). 9M 2020
2020-11-12 English
Investor Presentation 2020
Investor Presentation Classification · 99% confidence The document is titled "Company Presentation Q1-Q3 2020 November 2020" and contains detailed financial highlights (Sales, EBIT, Balance Sheet, Cash Flow) for the first three quarters of 2020, along with updates on R&D projects (COVID-19 therapies, Trimodulin, IgG Next Generation) and operational progress (Biotest Next Level). It includes a financial calendar listing future reports and an AGM date. This structure—a detailed presentation summarizing performance over a multi-quarter period, often used for investor briefings or internal reviews—strongly aligns with the definition of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K or IR, nor is it a short announcement (RPA/RNS).
2020-11-12 German
Investor Presentation 2020
Investor Presentation Classification · 99% confidence The document is titled "Company Presentation Q1-Q3 2020 November 2020" and contains detailed financial highlights (Sales, EBIT, Balance Sheet, Cash Flow) for the first three quarters of 2020, along with updates on R&D projects (COVID-19 therapies, Trimodulin, IgG Next Generation) and operational progress (Biotest Next Level). It includes a financial calendar listing future reports and an AGM date. This structure—a detailed presentation summarizing performance over a multi-quarter period, often used for investor briefings or internal reviews—strongly aligns with the definition of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K or IR, nor is it a short announcement (RPA/RNS).
2020-11-12 English
Q3 statement / Q3 financial report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'QUARTERLY STATEMENT 1 JANUARY TO 30 SEPTEMBER 2020' and contains detailed financial statements, including consolidated income, financial position, and cash flow statements, as well as management's analysis of business performance and the impact of COVID-19. It is a comprehensive report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2020
2020-11-12 German

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.